Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | SLC10A6 | Q3KNW5 | 2/20 | 0.52 |
| ▸ | SLC10A2 | Q12908 | 1/20 | 0.52 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 6/20 | 0.50 |
| ▸ | CA2 | P00918 | 6/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.44 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SLC20A2 | Q08357 | 1/20 | 0.43 |
| ▸ | SLC20A1 | Q8WUM9 | 1/20 | 0.43 |
| ▸ | GPR27 | Q9NS67 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5119532 | 0.86 | CA12 (0.68) | KDM4EPOLBSLC10A6SLC10A2SLC10A1 | |
| SCHEMBL5119488 | 0.82 | CA9 (0.63) | KDM4EMAPTSLC10A6SLC10A2SLC10A1 | |
| SCHEMBL5124261 | 0.77 | SLC10A6 (0.61) | KDM4EMAPTSLC10A6SLC10A2SLC10A1 | |
| SCHEMBL6754585 | 0.76 | SLC10A6 (0.81) | KDM4EPOLBSLC10A6SLC10A2SLC10A1 | |
| SCHEMBL491893 | 0.75 | SLC10A6 (0.63) | KDM4EMAPTSLC10A6SLC10A2SLC10A1 | |
| SCHEMBL5110940 | 0.75 | SLC10A6 (0.68) | KDM4ESLC10A6SLC10A2SLC10A1MEN1 | |
| SCHEMBL492283 | 0.73 | SLC10A6 (0.69) | KDM4EPOLBSLC10A6SLC10A2SLC10A1 | |
| SCHEMBL5111324 | 0.73 | SLC10A6 (0.69) | KDM4EPOLBSLC10A6SLC10A2SLC10A1 | |
| SCHEMBL5111523 | 0.73 | SLC10A6 (0.61) | MAPTPOLBSLC10A6SLC10A2SLC10A1 | |
| SCHEMBL5111386 | 0.72 | GPR27 (0.62) | KDM4ESLC10A6SLC10A2SLC10A1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7351703-B2 | Sulfonylamino carboxylic acid N-arylamides as guanylate cyclase activators | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-04-01 | — | — | US | disclosed |
| US-20050080073-A1 | Sulfonylaminocarboxiylic acid N-arylamides as guanylate cyclase activators | AVENTIS PHARMA DEUTSCHLAND GMBH | 2005-04-14 | — | — | US | disclosed |
| US-6809089-B2 | FOR THERAPY AND PROPHYLAXIS OF CARDIOVASCULAR DISORDERS SUCH AS HIGH BLOOD PRESSURE, ANGINA PECTORIS, CARDIAC INSUFFICIENCY, THROMBOSES OR ATHEROSCLEROSIS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-10-26 | — | — | US | disclosed |
| US-20030171352-A1 | Sulfonylaminocarboxylic acid N-arylamides as guanylate cyclase activators | AVENTIS PHARMA DEUTSCHLAND GMBH | 2003-09-11 | — | — | US | disclosed |
| US-6548547-B1 | Cardiovascular disorders; hypotensive agents, antiasthmatics, cognition activators | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-04-15 | — | — | US | disclosed |
| EP-1095015-A2 | SULFONYLAMINO CARBOXYLIC ACID N-ARYLAMIDES AS GUANYLATE CYCLASE ACTIVATORS | Aventis Pharma Deutschland GmbH (DE) | 2001-05-02 | — | — | EP | disclosed |
| WO-2000002850-A2 | SULFONYLAMINO CARBOXYLIC ACID N-ARYLAMIDES AS GUANYLATE CYCLASE ACTIVATORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080073-A1 | Sulfonylaminocarboxiylic acid N-arylamides as guanylate cyclase activators | GUCY1A1, GUCY1B1, GUCY1A2 | KDM4E 4187/4885MAPT 4869/4885POLB 4123/4885 |
| US-20030171352-A1 | Sulfonylaminocarboxylic acid N-arylamides as guanylate cyclase activators | GUCY1A1, GUCY1B1, GUCY1B2 | KDM4E 3666/4885MAPT 4871/4885POLB 4097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.